Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Classical hematology 1

Conditions

Lymphoma, T-Cell 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 56ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Iodine-131 × Lymphoid × Clear all
NCT00860171 2020-04-03

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
16 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡